Table 1.
Mechanical properties of cancerous cells measured by AFM, treated mainly with taxol.
| Drug | Cell Type | Dose Time |
Elasticity Change (E) | Reference |
|---|---|---|---|---|
| Paclitaxel | prostate cancer (PC-3) |
2 and 10 µM 24 h |
E ↑ | Ren et al. 2015 [39] |
| Docetaxel | prostate cancer (22Rv) |
150 nM 24 h |
E ↑ | Raudenska et al. [66] |
| Docetaxel | prostate cancer (PC-3) |
200 nM 24 h |
E ↑ | Raudenska et al. [66] |
| Paclitaxel | melanoma (B16F10) |
24 nM 14 h |
no change | Lin et al. [67] |
| Paclitaxel | melanoma (B16F10) |
287 nM 30 h |
E ↓ | Lin et al. [67] |
| Paclitaxel | melanoma (B16F10) |
20 nM 30 h |
no change | Lin et al. [67] |
| Paclitaxel | melanoma (B16F10) |
42 nM 46 h |
E ↓ | Lin et al. [67] |
| Paclitaxel | endometrial cancer (Ishikawa cells) |
50 µM 6–18h h |
E ↓ | Kim et al. [63] |
| Colchicine | hepatocellular carcinoma (SMCC-7721) |
0.1 µM 2h |
no change | Liu et al. [68] |
| Colchicine | hepatocellular carcinoma (SMCC-7721) |
0.1 µM 4 and 6 h |
E ↑ | Liu et al. [68] |